Arcellx’s Promising Clinical Data and Strong Financial Position Justify Buy Rating with $105 Target Price

In a report released today, Gil Blum from Needham maintained a Buy rating on Arcellx Inc, with a price target of $105.00.

Gil Blum has given his Buy rating due to a combination of factors including the promising clinical data from Arcellx’s iMMagine-1 study, which demonstrated sustained response and no delayed neurotoxicities over a median follow-up period of 12.6 months. This positive outcome suggests a reduced risk for the potential approval of anito-cel in relapsed/refractory multiple myeloma (r/r MM), with expectations for a market launch by mid-to-late 2026.
Additionally, Arcellx’s financial position is robust, as evidenced by its $576 million cash reserve at the end of the third quarter of 2025, which supports its operations well into 2028. The company’s ongoing efforts, such as the iMMagine-3 study and the recent IND clearance for the ACLX-004 program, further bolster its growth prospects and justify the Buy rating with a target price of $105.

In another report released yesterday, Truist Financial also reiterated a Buy rating on the stock with a $134.00 price target.